#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687

• https://x.com/Yuz6Yusof/status/1933397540470182033/photo/1

#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b

• https://x.com/Yuz6Yusof/status/1933460933751238740/photo/1

#EULAR2025 Abstr#POS0318 Single timepoint assessment may not show true picture of #SLE control. Data from BILAG-BR registry using machine learning showed 6 trajectories with clinical meaning: -Nonresponse with high activity: dsDNA-ve & RNP+ -Response-flare: active MSK @RheumNow https://t.co/VrI8e4ONtM

• https://x.com/Yuz6Yusof/status/1933489456524206157/photo/1

#WIN in systemic sclerosis (SSc): -Ongoing trials now targeting multiple pathways. -CONQUEST platform may reshape research in Ssc and other autoimmune diseases. -Revised CRISS could replace single organ endpoints for approval. #EULAR2025 @RheumNow https://t.co/kxSeFb5lAU

• https://x.com/AdelaCastro222/status/1933872420135289278/photo/1
• https://x.com/AdelaCastro222/status/1933872420135289278/photo/1
• https://x.com/AdelaCastro222/status/1933872420135289278/photo/1

+RCT in #pSjD #Sjogrens #Disease #Leflunomide + #hydroxychloroquine Vs #PBO 2nd study to show this - same group need to know ▶️what pt to use this in ▶️is there diff organ improvements ⬆️#ESSDAI ⬇️RF ⬇️Ig’s Easy to prescribe ?early, mild dx #EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6

• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1

#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow

In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA

• https://x.com/synovialjoints/status/1933900613902893138/photo/1

What ‘CAR’ to drive? #CAR-T buzz was at #EULAR2025 In multiple #rheumatic #diseases #SLE #Scleroderma #Sjogrens #myositis Even #axial #SpA Who - active, not a lot of damage Which target 🎯 Which priming regiment What will results be compared to? Who will pay? @RheumNow

APEX study showed significant inhibition of structural damage progression with both dosing regimens (Q4W and Q8W) of GUS (IL-23i) in biologic-naïve pts with active PsA. Abstract #LB0010 #EULAR2025 @RheumNow https://t.co/QxYAPGB67v

• https://x.com/AdelaCastro222/status/1933909351694991541/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD). https://t.co/2zuxF1PY3Q. https://t.co/Icck4qE76X

• Psoriatic Arthritis at Risk for Interstitial Lung Disease | RheumNow

Late-Onset Disease: Different Age, Different Rules? We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/ubVRhhRGxG

#Enpatoran a #TLRi in Phase2 #SLE #RCT -previous data + small #cutaneous #lupus study various doses &PBO approx 25/group Interesting data - seems to ⬇️#IFN + endpoints 👀 for more to come! Safe so far #EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX

• https://x.com/Janetbirdope/status/1933865825825374650/photo/1
• https://x.com/Janetbirdope/status/1933865825825374650/photo/1
• https://x.com/Janetbirdope/status/1933865825825374650/photo/1

Biologic switching in PsA: -Retrospective study on 3,851 PsA pts initiating bDMARDs, 1,848 (48%) switched therapy at least once. -TNFis were the initial therapy. -IL17i were the first switch in both single-switch and multi-switch scenarios. -Subsequent switches: back to TNFi https://t.co/tJDJvPeu9T

• https://x.com/AdelaCastro222/status/1933868029126815893/photo/1